



Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens

Hong-Yu Cheng[†], Meng-Xia Ning[†], De-Kun Chen^{*} and Wen-Tao Ma^{*}

Veterinary Immunology Laboratory, College of Veterinary Medicine, Northwest Agriculture and Forestry University, Yangling, China

OPEN ACCESS

Edited by:

Sudhanshu Shekhar,
University of Oslo, Norway

Reviewed by:

Matthieu Million,
IHU Mediterranee Infection, France
Fei Teng,
Cornell University, United States
Esen Sefik,
Yale University, United States

*Correspondence:

De-Kun Chen
cdk@nwfau.edu.cn
Wen-Tao Ma
mawentao@nwfau.edu.cn

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology

Received: 30 November 2018

Accepted: 07 March 2019

Published: 29 March 2019

Citation:

Cheng H-Y, Ning M-X, Chen D-K and
Ma W-T (2019) Interactions Between
the Gut Microbiota and the Host
Innate Immune Response Against
Pathogens. *Front. Immunol.* 10:607.
doi: 10.3389/fimmu.2019.00607

The mammalian intestine is colonized by over a trillion microbes that comprise the “gut microbiota,” a microbial community which has co-evolved with the host to form a mutually beneficial relationship. Accumulating evidence indicates that the gut microbiota participates in immune system maturation and also plays a central role in host defense against pathogens. Here we review some of the mechanisms employed by the gut microbiota to boost the innate immune response against pathogens present on epithelial mucosal surfaces. Antimicrobial peptide secretion, inflammasome activation and induction of host IL-22, IL-17, and IL-10 production are the most commonly observed strategies employed by the gut microbiota for host anti-pathogen defense. Taken together, the body of evidence suggests that the host gut microbiota can elicit innate immunity against pathogens.

Keywords: gut microbiota, host innate immunity, antimicrobial peptides, inflammasome, IL-22, IL-17, IL-10

INTRODUCTION

The mammalian intestine is home to a complex and dynamic population of microorganisms, termed the “gut microbiota” (1, 2). These microorganisms, which co-evolved with the host as part of a mutually beneficial relationship (3), include bacteria, fungi and viruses (4, 5). Accumulating evidence indicates that the gut microbiota can participate in the maturation and function of the innate immune system, while also playing many complex roles in the host defense against pathogens (6). On the one hand, the gut microbiota can help repair intestinal mucosal barrier damage (7, 8); on the other hand, gut microbiota mediates host anti-pathogen defenses (9).

In the past decade, studies of germ-free (GF) mice have provided clues to elucidate the complexity of the intestinal microbiota (10, 11) and its importance to host health (12, 13). Mounting research shows that at least a thousand different gut microbiota species, such as *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, *Proteobacteria*, and others, contribute to host defense against harmful microorganisms (14, 15).

Recently, several studies have begun to elucidate the molecular mechanisms underlying how the gut microbiota regulates host innate immunity against pathogens (16, 17), including a role in helping the host resist pathogen colonization. In this review, we summarize the main mechanisms by which commensal bacteria, including certain probiotic species, actively prevent pathogen colonization of the host.

GUT MICROBIOTA AND ANTIMICROBIAL PEPTIDES

Defensins

The α -defensins, microbicidal peptides mainly produced by Paneth cells, are key components of innate immunity. They control pathogen growth within the intestine (18–20) and their production can be directly elicited by both Gram-negative and Gram-positive bacteria, as well as by bacterial metabolites (e.g., lipopolysaccharide, lipoteichoic acid, lipid A, and muramyl dipeptide) (21–23). By contrast, live fungi and protozoa do not appear to stimulate Paneth cells and thus fail to elicit Paneth cell degranulation (21). Nevertheless, recent research has found that the gut microbiota plays an important role in induction of α -defensins expression against pathogens (24). In one *in vitro* study, live *E. coli* or *S. aureus*, live or dead *S. typhimurium*, lipopolysaccharide (LPS), lipid A, lipoteichoic acid (LTA), or liposomes could stimulate isolated intact intestinal crypts, demonstrating that intestinal Paneth cells may contribute to α -defensins secretion by sensing the presence of exogenous bacteria and bacterial antigens (21). To investigate whether gut microbiota possess the same or similar functions, Shipra Vaishnav and colleagues used a CR2-MyD88 Tg mouse model, whereby Paneth cells were the sole cell lineage expressing MyD88, to demonstrate that Paneth cells may directly sense enteric bacteria to trigger the MyD88-dependent antimicrobial program. Furthermore, increased numbers of *Salmonella* were observed to be internalized by mesenteric lymph node (MLN) cells of MyD88^{-/-} and germ-free mice as compared to corresponding numbers observed for wild-type mice (25). Similarly, transcriptional profiles have shown that α -defensin gene (*Defa*) transcripts were less abundant in intestinal microbiota-free mice and TLRs-deficient or MyD88-deficient mice, but could be recovered after stimulation with toll-like receptor (TLR) agonists, specifically agonists of TLR2 or TLR4 (26). Thus, commensal microbiota appears to protect the host against pathogen invasion by triggering enteric Paneth cell TLR-MyD88 signaling. Notably, this mechanism is distinct from the NOD2-dependent antimicrobial response (25, 27, 28), since the former mechanism entails triggering of expression of multiple antimicrobial factors (25). However, several human-based studies have demonstrated that mutations in the NOD2 peptidoglycan sensor actually did reduce secretion of α -defensins (29–33). Therefore, these contradictory human and mouse study results warrant further research. Notably, another study has demonstrated that Cd1d^{-/-} mice exhibited a defect in Paneth cell granule ultrastructure that specifically resulted in an inability to degranulate after bacterial colonization, with an increased load of segmented filamentous bacteria (SFB) also noted (34). Thus, no clear evidence demonstrates that CD1d mediates regulation of gut microbiota via α -defensins expression.

Meanwhile, more recent research has begun to examine the mechanism of how the gut microbiota influences α -defensins secretion. Studies using the Caco-2 IEC line have demonstrated that lactic acid strongly suppresses transcription of the α -defensin gene, while cecal content may include as yet unidentified factors which enhance concomitant α -defensin 5 expression (35).

However, contrary to the aforementioned results, Menendez et al. found that *Defa* expression was partially restored *in vivo* by *Lactobacillus* administration to antibiotic-treated mice (26). Notably, an emerging role of vitamin D, a *Lactobacillus* metabolite, has been recently discovered that exerts an effect opposite on α -defensins expression to that exerted by lactate (36, 37). To reconcile these results, Su et al. used a mouse model and certain feed formulations to demonstrate that VDD- and HFD \pm VDD-fed mice exhibited reduced levels of expression of α -defensin and MMP7 (a metalloproteinase that can proteolytically convert pro- α -defensins to their mature and active forms) within ileal crypts as compared to results for control and HFD groups. Moreover, their results demonstrated a critical role of vitamin D signaling in maintaining steady-state expression of α -defensins and MMP7 under physiological conditions. Subsequently, Su et al. have demonstrated that dietary vitamin D deficiency resulted in loss of Paneth cell-specific α -defensins, which may lead to intestinal dysbiosis and endotoxemia (38). Of note, oral administration of α -defensin suppressed *Helicobacter hepaticus* growth *in vivo* (38). Meanwhile, using complementary mouse models of defensin deficiency (MMP7^{-/-}) and surplus (HD5^{+/+}), Salzman noted defensin-dependent reciprocal shifts in proportions of dominant bacterial species within the small intestine with no changes in total bacterial numbers observed (Table 1). Upon further research, this group observed that mice overexpressing HD5 exhibited a significant loss of segmented filamentous bacteria (SFB), resulting in reduced numbers of Th17 cells within the lamina propria (48). However, direct evidence implicating the involvement of SFB in α -defensin production is still lacking and studies on α -defensin regulation by specific commensal microorganisms are still rare, warranting further research. Nevertheless, in view of existing research results, we believe that the discovery of specific microorganisms through research focusing on specific metabolic pathways may be a more fruitful approach.

With regard to β -defensins, which directly kill or inhibit the growth of microorganisms (49), these agents have been shown to exert antimicrobial activity against some species of enteric pathogenic Gram-positive *S. aureus* and *S. pyogenes*, as well as against Gram-negative *P. aeruginosa*, *E. coli* and the yeast *C. albicans* (50). In fact, accumulating evidence has shown that, similarly to α -defensins, β -defensins secretion is also regulated by the gut microbiota. For example, using *in vitro* studies of HT-29 and Caco-2 human colon epithelial cell lines, human fetal intestinal xenografts have been observed to constitutively express hBD-1 but not hBD-2, with upregulation of only the latter in xenografts intraluminally infected with *Salmonella* (51). Meanwhile, it has been independently shown that preincubation of Caco-2 cells with live *E. faecium* significantly reduced *S. typhimurium* internalization by 45.8%, while heat-killed *E. faecium* pretreatment had no effect on pathogen internalization (49). This result aligns with the latest research, which has shown that only live gut microbiota, as modeled using *Lactobacillus acidophilus* PZ 1129 and PZ 1130, *Lactobacillus paracasei*, *Lactobacillus plantarum*, *E. coli* K-12, and *E. coli* Nissle 1917, can strongly induce expression of hBD-2 in Caco-2 intestinal epithelial cells in a time- and dose-dependent manner (39–42).

TABLE 1 | Gut microbiota protects the host against pathogen infections and the relevant mechanisms.

Pathogens	Gut microbiota	Mechanisms	References
<i>Helicobacter hepaticus</i>	<i>Lactobacillus</i>	Inducing α -defensin production from Paneth cells	(38)
<i>S. aureus</i>	<i>Lactobacillus acidophilus</i> PZ 1129	Inducing β -defensin production	(39–42)
<i>S. pyogenes</i>	<i>Lactobacillus acidophilus</i> PZ 1130		
<i>P. aeruginosa</i>	<i>Lactobacillus paracasei</i>		
<i>E. coli</i>	<i>Lactobacillus plantarum</i>		
<i>C. albicans</i>	<i>E. coli</i> K-12 <i>E. coli</i> Nissle 1917		
<i>Klebsiella pneumoniae</i>	<i>L. reuteri</i>	Inducing IL-22 production	(43–46)
<i>Citrobacter rodentium</i>	<i>Allobaculum</i> spp	Inducing IL-17 production	(47)
<i>Enterococcus</i>	<i>Clostridium</i> spp		
<i>Plasmodium chabaudi</i>	<i>Bacteroides</i> spp		
<i>Salmonella typhimurium</i>	<i>Bacteroides</i>		

(Table 1). Notably, the *E. coli* strain Nissle 1917, a non-pathogenic Gram-negative strain isolated in 1917 by Alfred Nissle, elicited the most marked expression of induced β -defensin expression *in vitro* (39–42). Interestingly, Schlee et al. constructed several *E. coli* Nissle 1917 deletion mutants and pinpointed flagellin as the major stimulatory factor for triggering of β -defensin secretion in the presence of that strain (40). Meanwhile, Wehkamp et al. and others have found that *E. coli* Nissle 1917-induced β -defensin expression in cell culture was mediated by NF- κ B- and MAPK/AP-1-dependent pathways (39–42). Nevertheless, *in vivo* studies are still needed to confirm if gut microbiota can induce β -defensins expression to reduce pathogen colonization and control gut homeostasis (Table 1). Recently, to further clarify the relationship between gut microbiota and β -defensin secretion, Miani et al. used a mouse model and antibiotic treatment experiments to study the participation of dysbiotic microbiota and a low-affinity aryl hydrocarbon receptor (AHR) allele in the defective pancreatic expression of mBD14 observed in NOD mice. By utilizing 16S rDNA gene sequencing and AHR ligand activity measurements, they demonstrated that gut microbiota-derived molecules, including AHR ligands and butyrate, promoted IL-22 secretion by pancreatic ILCs that subsequently induced mBD14 expression by endocrine cells. Therefore, dysbiotic microbiota and a low-affinity AHR allele appear to explain defective pancreatic mBD14 expression of mBD14 in NOD mice (24). Because only live gut microbiota can stimulate secretion of β -defensins, we believe that specific gut microbiota that possess special metabolic pathway functionality, including pathways for secretion of AHR ligands, may possess the ability to regulate secretion of β -defensins.

C-Type Lectins

The C-type lectins, also key components of innate immunity that control growth of enteric pathogens (52–54), are expressed by multiple small intestinal epithelial lineages (55, 56). REG3 γ and REG3 β , two C-type lectins, provide protection against infection by specific bacterial pathogens, including *Enterococcus faecalis* (57–59), *Yersinia pseudotuberculosis* (60, 61), and *Listeria monocytogenes* (57). Notably, additional evidence suggests that C-type lectins actually mediate syncytium endosymbiont defenses through prevention of pathogen colonization. To

further demonstrate how these lectins control bacterial colonization of the intestinal epithelial surface, Vil-Myd88^{Tg} mice (mice with IEC-restricted Myd88 expression) were used to determine whether surface Myd88 present on epithelial cells was sufficient to restrain bacterial colonization (55). The results showed that secretion of C-type lectins required both activation of the MyD88 pathway (62) and recognition of syncytium endosymbionts by TLRs (63). Furthermore, Earle et al. used a pipeline method to assess intestinal microbiota localization within immunofluorescence images of fixed gut cross-sections. The results indicated that elimination of dietary microbiota-accessible carbohydrates (MACs) resulted in thinning of mucus within the distal colon that increased microbial proximity to the epithelium and heightened inflammatory marker REG3 β expression (64). These results align with those from an earlier study of transcriptional profiles of duodenum, jejunum, ileum and colon samples, which demonstrated that MyD88 was essential for syncytium endosymbiont-induced colonic epithelial expression of antimicrobial genes Reg3 β and Reg3 γ , with Myd88 deficiency associated with both a shift in bacterial diversity and a greater proportion of SFB in the small intestine (65). In fact, other research found that conventionally raised Myd88^{-/-} mice exhibited increased expression of antiviral genes in the colon, which correlated with norovirus infection of the colonic epithelium (65). Therefore, it can be concluded that both the activation of the MyD88 pathway and recognition of syncytium endosymbionts by TLRs are indispensable for triggering C-type lectins secretion (Figure 1). Recently, Ju et al. used antibiotic-treated mice to study differences between metronidazole-treated and control groups, and observed reduced abundance of *Turicibacteraceae*, overgrowth of *E. coli* and higher levels of Reg3 β and Reg3 γ mRNA for the metronidazole-treated group (66). These results provide a basis for the study of the effects of specific gut syncytium endosymbiont organisms on C-type lectins secretion.

Other accumulating evidence has shown that the mammalian gut contains a rich fungal community that interacts with the immune system through the C-type lectin receptor Dectin-1. To demonstrate whether symbiotic fungi influence C-type lectins secretion that prevents pathogen colonization, Iliev et al. studied mice lacking Dectin-1 and observed increased susceptibility




FIGURE 1 | Gut microbiota plays an important role in the induction of antimicrobial peptides expression against pathogens. Antimicrobial peptides are key components of innate immunity to control pathogen growth within the intestine. Accumulated evidence identified that gut microbiota can contribute to the expression of antimicrobial peptides and play a central role in host defense against pathogens. Paneth cells could directly sense gut microbiota through cell-autonomous myeloid differentiation primary response 88 (MyD88)-dependent toll-like receptor (TLR) activation, triggering expression of α -defensins and C-type lectins. With regard to β -defensin, gut microbiota induce β -defensin expression in cell culture mediated by NF- κ B- and MAPK/AP-1-dependent pathways *in vitro*. Then β -defensin interacts with intestinal epithelial cell (IEC) through CCR6 to activate epithelial restitution and barrier repair.

to chemically induced colitis due to altered responses to indigenous fungi. Moreover, in humans they identified a gene polymorphism for Dectin-1 (CLEC7A) that is strongly linked to a severe form of ulcerative colitis (67). Independently, Eriksson et al. found that CLR-specific intracellular adhesion molecule-3 grabbing non-integrin homolog-related 3 (SIGNR3) is the closest murine homolog to the human dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Both receptors recognize similar carbohydrate ligands, such as terminal fucose or high-mannose glycans. Notably, using the dextran sulfate sodium-induced colitis model, IGNR3 has been observed to recognize fungal members of the commensal microbiota, with SIGNR3^{-/-} mice exhibiting a higher level of TNF- α in colon (68). Therefore, symbiotic fungi appear to communicate with the host via the C-type lectin receptor to maintain intestinal homeostasis. However, as yet no direct evidence has been found to determine whether symbiotic fungi can regulate selectin secretion, warranting further research.

GUT MICROBIOTA ELICITS INFLAMMASOME ACTIVATION AGAINST PATHOGENS

Inflammasome activation is an important innate immune pathway that prevents pathogen invasion via secretion of proinflammatory cytokines IL-1 β and IL-18, as well as through induction of pyroptosis (69–74). It is well-documented that

inflammasomes come from two main sources, namely myeloid- and epithelial-derived inflammasomes. While they share several common features, it should be noted that inflammasomes of distinct origins may exhibit different features and effector functions. For example, from a mechanistic view, macrophage- and epithelial cell-derived inflammasomes are activated with different intermediate processes. While IL-18 processing is dependent on caspase-11 in IECs, caspase-1 is responsible for the processing of IL-18 in myeloid cells (75). In addition, compared with myeloid cells, IECs constitutively express IL-18, while produce little IL-1 β (76–78). Moreover, unlike myeloid inflammasomes, IEC inflammasomes is capable of producing considerable amounts of prostaglandin upon activation (79). Intriguingly, the signaling circuitry between epithelial and myeloid inflammasomes are also different. For example, in homeostasis conditions, both *NLRP3* and *PYCARD* genes have been shown to be highly expressed in murine primary macrophages, while mouse airway epithelial cells can only express a low level of *PYCARD* and cannot express *NLRP3* (80).

Accumulating evidence suggests that gut microbiota can activate NLRC4 and NLRP3 inflammasome pathways against pathogens (81–83). *Enterobacteriaceae* and the pathobiont *Proteus mirabilis*, which are members of the normal flora of the human gastrointestinal tract (84, 85), were shown to induce robust IL-1 β production through NLRP3 activation mediated by intestinal Ly6C^{high} monocytes (86, 87). Indeed, recruited Ly6C^{high} monocytes have been shown to express a variety of inflammasome components, such as NAIPs (71, 88, 89), NLRC4

(89), NLRP1 (90, 91), NLRP6 (92, 93), AIM2 (94), caspase-1 (95), caspase-4 (96) (in humans), ASC (93), and IL-18 (87, 97, 98). Meanwhile, Seo et al. have also demonstrated that *Proteus mirabilis* (a Proteobacteria phylum member) induced NLRP3 activation and IL-1 β production (86). Interestingly, bacterial components from other *Proteobacteria*, such as LPS produced by *Pseudomonas* spp., have even been shown to induce host mental depression symptoms via NLRP3 inflammasome activation (99). Other interesting lines of research have shown that in addition to gut commensal bacteria, the mammalian gut contains a rich fungal community which also appears to activate the inflammasome pathway. This community includes the human commensal fungus *Candida albicans* (*C. albicans*), which colonizes gastrointestinal and vaginal tract mucosal surfaces and appears to promote inflammasome activation during AOM-DSS-induced colitis (100). In further support of this finding, direct peptide administration experiments had previously demonstrated that candidalysin, a peptide derived from the hypha-specific *ECE1* gene, acted as a fungal trigger for NLRP3 inflammasome-mediated maturation that was sufficient for inducing IL-1 β secretion mature macrophages in an NLRP3 inflammasome-dependent manner (101).

In recent studies, numerous other gut microbiota metabolites have also been demonstrated to elicit inflammasome pathways against pathogens. For example, gut microbiota-derived adenosine triphosphate (ATP) has been shown to co-operate with NLRP3 (also known as CIAS1) (102) via the macrophage P2X7 receptor (103) to induce assembly of a cytosolic protein complex containing ASK and caspase-1 (70, 104–106) that eventually leads to inflammasome activation (106). Another important gut microbiota metabolite, short-chain fatty acids (SCFAs), end products of fermentation of dietary fibers by anaerobic intestinal microbiota, have also been implicated in inflammasome activation (107). SCFAs binding to GPR43 on colonic epithelial cells to stimulate K⁺ efflux and hyperpolarization has been shown to lead to NLRP3 inflammasome activation, with subsequent acceleration of cell maturation and secretion of IL-1 β (108) and IL-18 (77, 109).

GUT MICROBIOTA CAN ENHANCE INTERLEUKIN EXPRESSION TO CLEAR INVADING PATHOGENS

IL-22

IL-22 is important in maintaining mucosal barrier integrity and is produced by many different types of innate immune cells (110–113). This cytokine has been shown to play a host-protective role during infection by a wide range of pathogens, including *Klebsiella pneumoniae* (114), *Citrobacter rodentium* (115, 116), vancomycin-resistant *Enterococcus* (117, 118) and *Plasmodium chabaudi* (119). One IL-22-dependent mechanism involved in pathogen clearance involves the increased presence of antimicrobial proteins within the mucosa (120) that include the following: calprotectin and lipocalin-2, the latter of which binds to the siderophore enterochelin, with both acting to limit iron availability in the gut (120); C-type lectins, which

regenerate islet-derivative proteins Reg3 β and Reg3 γ that control some components of the microbiota (58, 120, 121); and S100A8 and S100A9, two antimicrobial peptides that heterodimerize to form calprotectin, an antimicrobial protein that sequesters zinc and manganese to prevent microbial access to these nutrients (122). Although epithelial antimicrobial defenses also exist, many pathogens can still colonize mucosal surfaces to establish infections (120, 123). Nevertheless, accumulated evidence has shown that IL-22 is rapidly induced in response to pathogen invasion through activation of host AhR via specific gut microbiota-derived molecules (**Figure 2**) (124, 125). For example, *Lactobacillus* species (specifically, *L. reuteri*) can activate IL-22 production by gut type 3 innate lymphoid cells (ILC3) (126–128), while other studies have shown that supplementation with three commensal *Lactobacillus* strains with high tryptophan-metabolizing activities was sufficient to restore intestinal IL-22 production (43, 129). Indeed, additional work has shown that *Lactobacillus* species could utilize tryptophan as an energy source and produce a metabolite, indole-3-aldehyde (IAld), which could then activate AhRs present on ILCs (126, 130). In addition to *Lactobacillus* strains, other recent studies have shown that *Allobaculum* spp. (43), *Escherichia coli* (44), *Clostridium* spp. (45), and *Bacteroides* spp. (46) can also utilize tryptophan to produce IAld and elicit IL-22 production (**Table 1**). Meanwhile, other studies have shown that activated ILCs secrete IL-22 to protect the host against opportunistic pathogens by reducing pathogen colonization (120, 131). In fact, other innate immune cells, such as NKT cells, $\gamma\delta$ T cells and macrophages, have very recently been shown to secrete IL-22 under regulation by gut microbiota via the AhR pathway (132). Therefore, gut microbiota may prevent pathogen infection by collectively enhancing IL-22 expression via the AhR pathway.

IL-17

IL-17 is a well-established crucial cytokine that is involved in limiting invasion and dissemination of pathogens, including *Salmonella typhimurium* (133), by both recruitment of neutrophils and by the induction of production of antimicrobial peptides (131, 134). Recent studies have demonstrated that both the abundance and activation status of IL-17-producing intraepithelial lymphocytes (IELs) are modulated by commensal bacteria, with enrichment of the $\gamma\delta$ T cell population of IELs representing an important source of innate IL-17 production (135, 136). Notably, a comparative study of GF mice and SPF mice has shown that the number of TCR $\gamma\delta$ IELs is decreased in GF mice (133). Moreover, in addition to the regulation of IELs numbers, the gut microbiota may also regulate activation of TCR $\gamma\delta$ IELs, as reflected by a report showing that production of IL-17 by TCR $\gamma\delta$ IELs is decreased in GF mice (137). Meanwhile, antibiotic-treatment and monoclonization of mice have been used to demonstrate that the great majority of $\gamma\delta$ T cells within peritonea of SPF mice are CD62L⁻ $\gamma\delta$ T cells, which are activated $\gamma\delta$ T cells, with GF mice possessing far fewer CD62L⁻ $\gamma\delta$ T cells than SPF mice (47). Notably, additional research suggests that specific commensal bacteria, excluding metronidazole-sensitive anaerobes, such as *Bacteroides* species, are required for maintaining IL-1R1[±] $\gamma\delta$ T cells (47), a result




FIGURE 2 | Gut microbiota enhance the expression of IL-22 against invading pathogens. IL-22 is important in maintaining the integrity of mucosal barriers and can be produced by many different types innate immune cells, which induce the expression of various antimicrobial proteins, including lipocalin-2, calprotectin, C-type lectins, S100A8, S100A9, and so on to clear pathogens. Increasing evidence identified that gut microbiota enhances the expression of IL-22 to protect the host against pathogens. The results show that gut microbiota utilize tryptophan as an energy source and produce a metabolite, indole-3-aldehyde (IAld), which in turns activated Ahr on innate immune cells. Once activated, innate immune cells will secrete IL-22, which protects the host against opportunistic pathogens by reducing their colonization.

that aligns with previous research results by another research group (138) (Table 1). In conclusion, gut microbiota influences the abundance and activation status of IL-17-producing TCR $\gamma\delta$ IELs to protect the host from pathogen infection and to maintain intestinal homeostasis. In addition, lymphoid tissue inducer (LTi) cells and NCR $^-$ ILC3 cells also appear to function as important sources of innate IL-17 production (127). However, few studies have investigated how gut microbiota regulate these cell types, warranting further research in this area.

IL-10

IL-10 is an anti-inflammatory cytokine that plays a central role in regulating the host immune response to pathogens, thereby preventing host damage and maintaining normal tissue homeostasis (139–141). Accumulating evidence suggests that macrophages are an important source of innate IL-10 and that the gut microbiota plays a vital role in mucosal innate IL-10 generation under homeostatic conditions (142–144). For example, studies in GF mice and SPF mice have shown that colonic lamina propria from germ-free mice exhibited lower IL-10 production (142), a reduction later confirmed to be a 50% reduction in steady-state IL-10 levels (142–144). To elucidate the mechanism by which gut microbiota regulate intestinal macrophage IL-10 production, Hayashi et al. used macrophage-specific IL-10-deficient mice to demonstrate that *Clostridium butyricum* (CB), a distinct cluster I *Clostridium* strain, induces IL-10 production to

ultimately prevent acute experimental colitis. However, while CB treatment had no effects on IL-10 production by T cells, IL-10-producing F4/80 $^+$ CD11b $^+$ CD11c int macrophages accumulated within inflamed mucosa after CB treatment. Subsequently, more rigorous examination demonstrated that CB directly triggered IL-10 production by intestinal macrophages there via the TLR2/MyD88 pathway (144). Meanwhile, Ochi et al. recently found that dietary amino acids directly regulate IL-10 production by small intestine (SI) macrophages. Using mice fed via total parenteral nutrition, a significant decrease of IL-10-producing macrophages in the SI was observed, while IL-10-producing CD4 $^+$ T cells remained intact. Likewise, enteral nutrient deprivation selectively decreased IL-10 production by the monocyte-derived F4/80 $^+$ macrophage population, but had no effect on non-monocytic precursor-derived CD103 $^+$ dendritic cells. Notably, in contrast to regulation of colonic macrophages, replenishment of SI macrophages and their IL-10 production were not regulated by gut microbiota (145). Contrary to results obtained under steady-state conditions, an injury model used to study participation of microbiota to explain observed IL-10 increases post-injury yielded different results. Specifically, comparison of *Ii10* mRNA levels in uninjured intact tissue and day-2 post-wound tissue isolated from SPF or GF mice indicated that IL-10 mRNA was induced in post-wound colonic tissue isolated from both SPF and GF mice. Therefore, injury-triggered IL-10 increases appeared to be largely microbiota independent (146), although the reasons

remain unclear regarding the differing effects of the gut microbiota observed in different model systems. Nevertheless, we hypothesize that local damage-associated molecular proteins (DAMPs) may regulate immune cells more rapidly and strongly post-intestinal damage, resulting in either a failure of gut microbiota to temporally adjust or a masking of any microbiota-based regulatory effect.

CONCLUDING REMARKS

Gut microbiota resists colonization and growth of invading pathogens through the induction of expression of antimicrobial peptides, IL-22, IL-17, and IL-10 while eliciting inflammasome activation. Because the underlying mechanisms of how the gut microbiota resists pathogenic invasion still remain obscure, future studies are clearly needed to identify gut microbiota functions against various pathogens toward the development of promising strategies to treat infectious diseases. For instance, *E. coli* Nissle 1917 can induce β -defensin expression mediated by NF- κ B- and MAPK/AP-1-dependent pathways (39), while *Lactobacillus* spp. activate IL-22 production against opportunistic pathogens to reduce colonization (147, 148). Therefore, transplanting suitable specific gut microbiota to compete with specific pathogens could be an effective defense strategy. However, since this strategy poses new disease risks, strategies that restore

intestinal homeostasis and promote host immune system may serve to more safely clear pathogens. To this end, identifying specific gut microbiota functions and defining normal gut microbiota populations are necessary first steps toward development of safer strategies for strengthening host defenses against pathogens. Moreover, research on the function and mechanisms of gut microbiota metabolites may facilitate development of novel therapeutic strategies to combat drug-resistant pathogens.

AUTHOR CONTRIBUTIONS

D-KC, W-TM, H-YC, and M-XN designed the structure of the mini-review. H-YC and M-XN wrote the manuscript and drafted the first version of the manuscript. M-XN and W-TM helped revise the manuscript. All authors have reviewed the final version of the manuscript.

FUNDING

This research was supported by the Qinghai province Major R&D and Transformation Project (2018-NK-125), Xianyang Science and Technology Major Project (2017K01-34), Key industrial innovation chains of Shaanxi province (2018ZDCXL-NY-01-06) and PhD research startup fund of Northwest Agriculture and Forestry University (00500/Z109021716).

REFERENCES

- Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol.* (2015) 21:8787–803. doi: 10.3748/wjg.v21.i29.8787
- Luthold RV, Fernandes GR, Franco-de-Moraes AC, Folchetti LG, Ferreira SR. Gut microbiota interactions with the immunomodulatory role of vitamin D in normal individuals. *Metabolism.* (2017) 69:76–86. doi: 10.1016/j.metabol.2017.01.007
- Ayres JS. Cooperative microbial tolerance behaviors in host-microbiota mutualism. *Cell.* (2016) 165:1323–31. doi: 10.1016/j.cell.2016.05.049
- Foca A, Liberto MC, Quirino A, Marascio N, Zicca E, Pavia G. Gut inflammation and immunity: what is the role of the human gut virome? *Mediators Inflamm.* (2015) 2015:326032. doi: 10.1155/2015/326032
- Chen B, Chen H, Shu X, Yin Y, Li J, Qin J, et al. Presence of segmented filamentous bacteria in human children and its potential role in the modulation of human gut immunity. *Front Microbiol.* (2018) 9:1403. doi: 10.3389/fmicb.2018.01403
- Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell.* (2014) 157:121–41. doi: 10.1016/j.cell.2014.03.011
- Okumura R, Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. *Exp Mol Med.* (2017) 49:e338. doi: 10.1038/emmm.2017.20
- Okumura R, Takeda K. Maintenance of intestinal homeostasis by mucosal barriers. *Inflamm Regen.* (2018) 38:5. doi: 10.1186/s41232-018-0063-z
- Ubeda C, Djukovic A, Isaac S. Roles of the intestinal microbiota in pathogen protection. *Clin Transl Immunol.* (2017) 6:e128. doi: 10.1038/cti.2017.2
- Biedermann L, Rogler G. The intestinal microbiota: its role in health and disease. *Eur J Pediatr.* (2015) 174:151–67. doi: 10.1007/s00431-014-2476-2
- Goulet O. Potential role of the intestinal microbiota in programming health and disease. *Nutr Rev.* (2015) 73 Suppl. 1:32–40. doi: 10.1093/nutrit/nuv039
- Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. *World J Gastroenterol.* (2014) 20:15163–76. doi: 10.3748/wjg.v20.i41.15163
- Kataoka K. The intestinal microbiota and its role in human health and disease. *J Med Invest.* (2016) 63:27–37. doi: 10.2152/jmi.63.27
- Gevers D, Knight R, Petrosino JF, Huang K, McGuire AL, Birren BW, et al. The human microbiome project: a community resource for the healthy human microbiome. *PLoS Biol.* (2012) 10:e1001377. doi: 10.1371/journal.pbio.1001377
- Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med.* (2016) 8:51. doi: 10.1186/s13073-016-0307-y
- Lim MY, You HJ, Yoon HS, Kwon B, Lee JY, Lee S, et al. The effect of heritability and host genetics on the gut microbiota and metabolic syndrome. *Gut.* (2017) 66:1031–8. doi: 10.1136/gutjnl-2015-311326
- Monedero V, Buesa J, Rodriguez-Diaz J. The interactions between host glycobiology, bacterial microbiota, and viruses in the gut. *Viruses.* (2018) 10:96. doi: 10.3390/v10020096
- Diamond G, Beckloff N, Weinberg A, Kisich KO. The roles of antimicrobial peptides in innate host defense. *Curr Pharm Des.* (2009) 15:2377–92. doi: 10.2174/138161209788682325
- Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. *Science.* (2012) 336:1268–73. doi: 10.1126/science.1223490
- Kim D, Zeng MY, Nunez G. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. *Exp Mol Med.* (2017) 49:e339. doi: 10.1038/emmm.2017.24
- Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouellette AJ. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. *Nat Immunol.* (2000) 1:113–8. doi: 10.1038/77783
- Elphick DA, Mahida YR. Paneth cells: their role in innate immunity and inflammatory disease. *Gut.* (2005) 54:1802–9. doi: 10.1136/gut.2005.068601
- Tanabe H, Ayabe T, Bainbridge B, Guina T, Ernst RK, Darveau RP, et al. Mouse paneth cell secretory responses to cell surface glycolipids of virulent

- and attenuated pathogenic bacteria. *Infect Immun.* (2005) 73:2312–20. doi: 10.1128/IAI.73.4.2312-2320.2005
24. Miani M, Le Naour J, Waeckel-Enee E, Verma SC, Straube M, Emond P, et al. Gut microbiota-stimulated innate lymphoid cells support beta-defensin 14 expression in pancreatic endocrine cells, preventing autoimmune diabetes. *Cell Metab.* (2018) 28:557–72.e6. doi: 10.1016/j.cmet.2018.06.012
 25. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. *Proc Natl Acad Sci USA.* (2008) 105:20858–63. doi: 10.1073/pnas.0808723105
 26. Menendez A, Willing BP, Montero M, Wlodarska M, So CC, Bhinder G, et al. Bacterial stimulation of the TLR-MyD88 pathway modulates the homeostatic expression of ileal Paneth cell alpha-defensins. *J Innate Immun.* (2013) 5:39–49. doi: 10.1159/000341630
 27. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. *Gastroenterology.* (2011) 140:1768–75. doi: 10.1053/j.gastro.2011.02.047
 28. Kong S, Zhang YH, Zhang W. Regulation of intestinal epithelial cells properties and functions by amino acids. *Biomed Res Int.* (2018) 2018:2819154. doi: 10.1155/2018/2819154
 29. Petnicki-Ocwieja T, Hrnčir T, Liu YJ, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. *Proc Natl Acad Sci USA.* (2009) 106:15813–8. doi: 10.1073/pnas.0907722106
 30. Ramanan D, Tang MS, Bowcutt R, Loke P, Cadwell K. Bacterial sensor Nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal *Bacteroides vulgatus*. *Immunity.* (2014) 41:311–24. doi: 10.1016/j.immuni.2014.06.015
 31. Shanahan MT, Carroll IM, Grossniklaus E, White A, von Furstenberg RJ, Barner R, et al. Mouse Paneth cell antimicrobial function is independent of Nod2. *Gut.* (2014) 63:903–10. doi: 10.1136/gutjnl-2012-304190
 32. Tan G, Zeng B, Zhi FC. Regulation of human enteric alpha-defensins by NOD2 in the Paneth cell lineage. *Eur J Cell Biol.* (2015) 94:60–6. doi: 10.1016/j.ejcb.2014.10.007
 33. Keestra-Gounder AM, Byndloss MX, Seyffert N, Young BM, Chavez-Arroyo A, Tsai AY, et al. NOD1 and NOD2 signalling links ER stress with inflammation. *Nature.* (2016) 532:394–7. doi: 10.1038/nature17631
 34. Nieuwenhuis EE, Matsumoto T, Lindenbergh D, Willemsen R, Kaser A, Simons-Oosterhuis Y, et al. Cd1d-dependent regulation of bacterial colonization in the intestine of mice. *J Clin Invest.* (2009) 119:1241–50. doi: 10.1172/JCI36509
 35. Sugi Y, Takahashi K, Kurihara K, Nakano K, Kobayakawa T, Nakata K, et al. a-Defensin 5 gene expression is regulated by gut microbial metabolites. *Biosci Biotechnol Biochem.* (2017) 81:242–8. doi: 10.1080/09168451.2016.1246175
 36. Jerzynska J, Stelmach W, Balcerak J, Woicka-Kolejwa K, Rychlik B, Blauz A, et al. Effect of *Lactobacillus rhamnosus* GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy. *Allergy Asthma Proc.* (2016) 37:324–34. doi: 10.2500/aap.2016.37.3958
 37. Shang M, Sun J. Vitamin D/VDR, probiotics, and gastrointestinal diseases. *Curr Med Chem.* (2017) 24:876–87. doi: 10.2174/0929867323666161202150008
 38. Su D, Nie Y, Zhu A, Chen Z, Wu P, Zhang L, et al. Vitamin D signaling through Induction of Paneth cell defensins maintains gut microbiota and improves metabolic disorders and hepatic steatosis in animal models. *Front Physiol.* (2016) 7:498. doi: 10.3389/fphys.2016.00498
 39. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by *Escherichia coli* Nissle 1917: a novel effect of a probiotic bacterium. *Infect Immun.* (2004) 72:5750–8. doi: 10.1128/IAI.72.10.5750-5758.2004
 40. Schlee M, Wehkamp J, Altenhoefer A, Oelschlaeger TA, Stange EF, Fellermann K. Induction of human beta-defensin 2 by the probiotic *Escherichia coli* Nissle 1917 is mediated through flagellin. *Infect Immun.* (2007) 75:2399–407. doi: 10.1128/IAI.01563-06
 41. Steubesand N, Kiehne K, Brunke G, Pahl R, Reiss K, Herzig KH, et al. The expression of the beta-defensins hBD-2 and hBD-3 is differentially regulated by NF-kappaB and MAPK/AP-1 pathways in an *in vitro* model of *Candida* esophagitis. *BMC Immunol.* (2009) 10:36. doi: 10.1186/1471-2172-10-36
 42. Seo EJ, Weibel S, Wehkamp J, Oelschlaeger TA. Construction of recombinant *E. coli* Nissle 1917 (EcN) strains for the expression and secretion of defensins. *Int J Med Microbiol.* (2012) 302:276–87. doi: 10.1016/j.ijmm.2012.05.002
 43. Etienne-Mesmin L, Chassaing B, Gewirtz AT. Tryptophan: A gut microbiota-derived metabolites regulating inflammation. *World J Gastrointest Pharmacol Ther.* (2017) 8:7–9. doi: 10.4292/wjgpt.v8.i1.7
 44. Devlin AS, Marcobal A, Dodd D, Nayfach S, Plummer N, Meyer T, et al. Modulation of a circulating uremic solute via rational genetic manipulation of the gut microbiota. *Cell Host Microbe.* (2016) 20:709–15. doi: 10.1016/j.chom.2016.10.021
 45. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. *Nat Commun.* (2018) 9:3294. doi: 10.1038/s41467-018-05470-4
 46. Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. *Nat Immunol.* (2011) 13:144–51. doi: 10.1038/ni.2187
 47. Duan J, Chung H, Troy E, Kasper DL. Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. *Cell Host Microbe.* (2010) 7:140–50. doi: 10.1016/j.chom.2010.01.005
 48. Salzman NH. Paneth cell defensins and the regulation of the microbiome: detente at mucosal surfaces. *Gut Microbes.* (2010) 1:401–6. doi: 10.4161/gmic.1.6.14076
 49. Fusco A, Savio V, Cammarota M, Alfano A, Schiraldi C, Donnarumma G. Beta-Defensin-2 and Beta-Defensin-3 reduce intestinal damage caused by *Salmonella typhimurium* modulating the expression of cytokines and enhancing the probiotic activity of *Enterococcus faecium*. *J Immunol Res.* (2017) 2017:6976935. doi: 10.1155/2017/6976935
 50. Harder J, Bartels J, Christophers E, Schroder JM. Characterization and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. *J Biol Chem.* (2001) 276:5707–13. doi: 10.1074/jbc.M008557200
 51. O'Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. *J Immunol.* (1999) 163:6718–24.
 52. Sotolongo J, Ruiz J, Fukata M. The role of innate immunity in the host defense against intestinal bacterial pathogens. *Curr Infect Dis Rep.* (2012) 14:15–23. doi: 10.1007/s11908-011-0234-4
 53. Katakura K, Watanabe H, Ohira H. Innate immunity and inflammatory bowel disease: a review of clinical evidence and future application. *Clin J Gastroenterol.* (2013) 6:415–9. doi: 10.1007/s12328-013-0436-4
 54. Thaiss CA, Levy M, Suez J, Elinav E. The interplay between the innate immune system and the microbiota. *Curr Opin Immunol.* (2014) 26:41–8. doi: 10.1016/j.coi.2013.10.016
 55. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, Koren O, et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. *Science.* (2011) 334:255–8. doi: 10.1126/science.1209791
 56. Thomas M, Pierson M, Uprety T, Zhu L, Ran Z, Sreenivasan CC, et al. Comparison of porcine airway and intestinal epithelial cell lines for the susceptibility and expression of pattern recognition receptors upon influenza virus infection. *Viruses.* (2018) 10:312. doi: 10.3390/v10060312
 57. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. *Nat Rev Immunol.* (2010) 10:131–44. doi: 10.1038/nri2707
 58. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. *Nat Rev Immunol.* (2012) 12:503–16. doi: 10.1038/nri3228
 59. Mukherjee S, Hooper LV. Antimicrobial defense of the intestine. *Immunity.* (2015) 42:28–39. doi: 10.1016/j.immuni.2014.12.028
 60. Dessen R, Gironella M, Vignal C, Peyrin-Biroulet L, Sokol H, Secher T, et al. Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of *Yersinia pseudotuberculosis*. *Gut.* (2009) 58:771–6. doi: 10.1136/gut.2008.168443
 61. Burger-van Paassen N, Loonen LM, Witte-Bouma J, Korteland-van Male AM, de Bruijn AC, van der Sluis M, et al. Mucin Muc2 deficiency and weaning influences the expression of the innate defense genes

- Reg3beta, Reg3gamma and angiogenin-4. *PLoS ONE*. (2012) 7:e38798. doi: 10.1371/journal.pone.0038798
62. Bel S, Pendse M, Wang Y, Li Y, Ruhn KA, Hassell B, et al. Paneth cells secrete lysozyme via secretory autophagy during bacterial infection of the intestine. *Science*. (2017) 357:1047–52. doi: 10.1126/science.aal4677
 63. Valentini M, Piermattei A, Di Sante G, Migliara G, Delogu G, Ria F. Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells. *J Immunol Res*. (2014) 2014:586939. doi: 10.1155/2014/586939
 64. Earle KA, Billings G, Sigal M, Lichtman JS, Hansson GC, Elias JE, et al. Quantitative imaging of gut microbiota spatial organization. *Cell Host Microbe*. (2015) 18:478–88. doi: 10.1016/j.chom.2015.09.002
 65. Larsson E, Tremaroli V, Lee YS, Koren O, Nookaew I, Fricker A, et al. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. *Gut*. (2012) 61:1124–31. doi: 10.1136/gutjnl-2011-301104
 66. Ju T, Shoblak Y, Gao Y, Yang K, Fouchse J, Finlay BB, et al. Initial gut microbial composition as a key factor driving host response to antibiotic treatment, as exemplified by the presence or absence of commensal *Escherichia coli*. *Appl Environ Microbiol*. (2017) 83:e01107-17. doi: 10.1128/AEM.01107-17
 67. Iliiev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science*. (2012) 336:1314–7. doi: 10.1126/science.1221789
 68. Eriksson M, Johannsen T, von Smolinski D, Gruber AD, Seeberger PH, Lepenius B. The C-type lectin receptor SIGNR3 binds to fungi present in commensal microbiota and influences immune regulation in experimental colitis. *Front Immunol*. (2013) 4:196. doi: 10.3389/fimmu.2013.00196
 69. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. *Nat Immunol*. (2009) 10:241–7. doi: 10.1038/ni.1703
 70. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1beta secretion. *Cytokine Growth Factor Rev*. (2011) 22:189–95. doi: 10.1016/j.cytogfr.2011.10.001
 71. Sahoo M, Ceballos-Olvera I, del Barrio L, Re F. Role of the inflammasome, IL-1beta, and IL-18 in bacterial infections. *ScientificWorldJournal*. (2011) 11:2037–50. doi: 10.1100/2011/212680
 72. Schmidt RL, Lenz LL. Distinct licensing of IL-18 and IL-1beta secretion in response to NLRP3 inflammasome activation. *PLoS ONE*. (2012) 7:e45186. doi: 10.1371/journal.pone.0045186
 73. Kanneganti TD. The inflammasome: firing up innate immunity. *Immunol Rev*. (2015) 265:1–5. doi: 10.1111/imr.12297
 74. He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. *Trends Biochem Sci*. (2016) 41:1012–21. doi: 10.1016/j.tibs.2016.09.002
 75. Crowley SM, Vallance BA, Knodler LA. Noncanonical inflammasomes: antimicrobial defense that does not play by the rules. *Cell Microbiol*. (2017) 19. doi: 10.1111/cmi.12730
 76. Knodler LA, Crowley SM, Sham HP, Yang H, Wrande M, Ma C, et al. Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. *Cell Host Microbe*. (2014) 16:249–56. doi: 10.1016/j.chom.2014.07.002
 77. Thinwa J, Segovia JA, Bose S, Dube PH. Integrin-mediated first signal for inflammasome activation in intestinal epithelial cells. *J Immunol*. (2014) 193:1373–82. doi: 10.4049/jimmunol.1400145
 78. Harrison OJ, Srinivasan N, Pott J, Schiering C, Krausgruber T, Iliot NE, et al. Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3(+) Treg cell function in the intestine. *Mucosal Immunol*. (2015) 8:1226–36. doi: 10.1038/mi.2015.13
 79. Rauch I, Deets KA, Ji DX, von Moltke J, Tenthorey JL, Lee AY, et al. NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8. *Immunity*. (2017) 46:649–59. doi: 10.1016/j.immuni.2017.03.016
 80. Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, et al. The NLRP3 inflammasome mediates *in vivo* innate immunity to influenza A virus through recognition of viral RNA. *Immunity*. (2009) 30:556–65. doi: 10.1016/j.immuni.2009.02.005
 81. Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S, et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. *Nat Immunol*. (2012) 13:449–56. doi: 10.1038/ni.2263
 82. Nordlander S, Pott J, Maloy KJ. NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen. *Mucosal Immunol*. (2014) 7:775–85. doi: 10.1038/mi.2013.95
 83. Levy M, Thaiss CA, Katz MN, Suez J, Elinav E. Inflammasomes and the microbiota—partners in the preservation of mucosal homeostasis. *Semin Immunopathol*. (2015) 37:39–46. doi: 10.1007/s00281-014-0451-7
 84. Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, et al. *Proteus mirabilis* bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. *Antimicrob Agents Chemother*. (2005) 49:2598–605. doi: 10.1128/AAC.49.7.2598-2605.2005
 85. Hardt WD. Journal club. An infection biologist points out an outstanding issue in mucosal immunology. *Nature*. (2009) 459:893. doi: 10.1038/459893e
 86. Seo SU, Kamada N, Munoz-Planillo R, Kim YG, Kim D, Koizumi Y, et al. Distinct commensals induce interleukin-1beta via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. *Immunity*. (2015) 42:744–55. doi: 10.1016/j.immuni.2015.03.004
 87. Ignacio A, Morales CI, Camara NO, Almeida RR. Innate sensing of the gut microbiota: modulation of inflammatory and autoimmune diseases. *Front Immunol*. (2016) 7:54. doi: 10.3389/fimmu.2016.00054
 88. Chen KW, Gross CJ, Sotomayor FV, Stacey KJ, Tschopp J, Sweet MJ, et al. The neutrophil NLRC4 inflammasome selectively promotes IL-1beta maturation without pyroptosis during acute *Salmonella* challenge. *Cell Rep*. (2014) 8:570–82. doi: 10.1016/j.celrep.2014.06.028
 89. Karki R, Lee E, Place D, Samir P, Mavuluri J, Sharma BR, et al. IRF8 regulates transcription of naips for NLRC4 inflammasome activation. *Cell*. (2018) 173:920–33.e13. doi: 10.1016/j.cell.2018.02.055
 90. Chi W, Li F, Chen H, Wang Y, Zhu Y, Yang X, et al. Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1beta production in acute glaucoma. *Proc Natl Acad Sci USA*. (2014) 111:11181–6. doi: 10.1073/pnas.1402819111
 91. Kaushal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B, et al. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. *Cell Death Differ*. (2015) 22:1676–86. doi: 10.1038/cdd.2015.16
 92. Chen GY, Liu M, Wang F, Bertin J, Nunez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. *J Immunol*. (2011) 186:7187–94. doi: 10.4049/jimmunol.1100412
 93. Levy M, Thaiss CA, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi JA, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. *Cell*. (2015) 163:1428–43. doi: 10.1016/j.cell.2015.10.048
 94. Micaroni M, Stanley AC, Khromykh T, Venturato J, Wong CX, Lim JB, et al. Rab6a/a' are important Golgi regulators of pro-inflammatory TNF secretion in macrophages. *PLoS ONE*. (2013) 8:e57034. doi: 10.1371/journal.pone.0057034
 95. Brough D, Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. *J Cell Sci*. (2007) 120(Pt 5):772–81. doi: 10.1242/jcs.03377
 96. Pallett MA, Crepin VF, Serafini N, Habibzay M, Kotik O, Sanchez-Garrido J, et al. Bacterial virulence factor inhibits caspase-4/11 activation in intestinal epithelial cells. *Mucosal Immunol*. (2017) 10:602–12. doi: 10.1038/mi.2016.77
 97. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nat Med*. (2015) 21:677–87. doi: 10.1038/nm.3893
 98. Thi HTH, Hong S. Inflammasome as a therapeutic target for cancer prevention and treatment. *J Cancer Prev*. (2017) 22:62–73. doi: 10.15430/JCP.2017.22.2.62
 99. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. *Neuro Endocrinol Lett*. (2008) 29:117–24. doi: 10.1016/j.jad.2012.02.023

100. Roselletti E, Perito S, Gabrielli E, Mencacci A, Pericolini E, Sabbatini S, et al. NLRP3 inflammasome is a key player in human vulvovaginal disease caused by *Candida albicans*. *Sci Rep.* (2017) 7:17877. doi: 10.1038/s41598-017-17649-8
101. Joly S, Ma N, Sadler JJ, Soll DR, Cassel SL, Sutterwala FS. Cutting edge: *Candida albicans* hyphae formation triggers activation of the Nlrp3 inflammasome. *J Immunol.* (2009) 183:3578–81. doi: 10.4049/jimmunol.0901323
102. Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in NLRP3 inflammasome activation. *Front Immunol.* (2012) 3:414. doi: 10.3389/fimmu.2012.00414
103. Amores-Iniesta J, Barbera-Cremades M, Martinez CM, Pons JA, Revilla-Nuin B, Martinez-Alarcon L, et al. Extracellular ATP activates the NLRP3 inflammasome and is an early danger signal of skin allograft rejection. *Cell Rep.* (2017) 21:3414–26. doi: 10.1016/j.celrep.2017.11.079
104. Franchi L, Kanneganti TD, Dubyak GR, Nunez G. Differential requirement of P2X7 receptor and intracellular K⁺ for caspase-1 activation induced by intracellular and extracellular bacteria. *J Biol Chem.* (2007) 282:18810–8. doi: 10.1074/jbc.M610762200
105. Dubyak GR. P2X7 receptor regulation of non-classical secretion from immune effector cells. *Cell Microbiol.* (2012) 14:1697–706. doi: 10.1111/cmi.12001
106. Franceschini A, Capece M, Chiozzi P, Falzoni S, Sanz JM, Sarti AC, et al. The P2X7 receptor directly interacts with the NLRP3 inflammasome scaffold protein. *FASEB J.* (2015) 29:2450–61. doi: 10.1096/fj.14-268714
107. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J Lipid Res.* (2013) 54:2325–40. doi: 10.1194/jlr.R036012
108. Grebe A, Hoss F, Latz E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. *Circ Res.* (2018) 122:1722–40. doi: 10.1161/CIRCRESAHA.118.311362
109. Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. *Immunity.* (2013) 38:1142–53. doi: 10.1016/j.immuni.2013.05.016
110. Mabuchi T, Takekoshi T, Hwang ST. Epidermal CCR6⁺ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasisiform dermatitis. *J Immunol.* (2011) 187:5026–31. doi: 10.4049/jimmunol.1101817
111. Malhotra N, Yoon J, Leyva-Castillo JM, Galand C, Archer N, Miller LS, et al. IL-22 derived from gammadelta T cells restricts *Staphylococcus aureus* infection of mechanically injured skin. *J Allergy Clin Immunol.* (2016) 138:1098–107.e93. doi: 10.1016/j.jaci.2016.07.001
112. Steinbach S, Vordermeier HM, Jones GJ. CD4⁺ and gammadelta T cells are the main producers of IL-22 and IL-17A in lymphocytes from *Mycobacterium bovis*-infected cattle. *Sci Rep.* (2016) 6:29990. doi: 10.1038/srep29990
113. Tyler CJ, McCarthy NE, Lindsay JO, Stagg AJ, Moser B, Eberl M. Antigen-presenting human gammadelta T cells promote intestinal CD4(+) T cell expression of IL-22 and mucosal release of calprotectin. *J Immunol.* (2017) 198:3417–25. doi: 10.4049/jimmunol.1700003
114. Xu X, Weiss ID, Zhang HH, Singh SP, Wynn TA, Wilson MS, et al. Conventional NK cells can produce IL-22 and promote host defense in *Klebsiella pneumoniae* pneumonia. *J Immunol.* (2014) 192:1778–86. doi: 10.4049/jimmunol.1300039
115. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat Med.* (2008) 14:282–9. doi: 10.1038/nm1720
116. Ota N, Wong K, Valdez PA, Zheng Y, Crellin NK, Diehl L, et al. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with *Citrobacter rodentium*. *Nat Immunol.* (2011) 12:941–8. doi: 10.1038/ni.2089
117. Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG. Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant *Enterococcus* infection. *J Infect Dis.* (2010) 201:534–43. doi: 10.1086/650203
118. Abt MC, Buffie CG, Susac B, Becattini S, Carter RA, Leiner I, et al. TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus. *Sci Transl Med.* (2016) 8:327ra325. doi: 10.1126/scitranslmed.aad6663
119. Sellau J, Alvarado CF, Hoenow S, Mackroth MS, Kleinschmidt D, Huber S, et al. IL-22 dampens the T cell response in experimental malaria. *Sci Rep.* (2016) 6:28058. doi: 10.1038/srep28058
120. Behnsen J, Jellbauer S, Wong CP, Edwards RA, George MD, Ouyang W, et al. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. *Immunity.* (2014) 40:262–73. doi: 10.1016/j.immuni.2014.01.003
121. Stelter C, Kappeli R, Konig C, Krah A, Hardt WD, Stecher B, et al. Salmonella-induced mucosal lectin RegIIIbeta kills competing gut microbiota. *PLoS ONE.* (2011) 6:e20749. doi: 10.1371/journal.pone.0020749
122. Hayden JA, Brophy MB, Cunden LS, Nolan EM. High-affinity manganese coordination by human calprotectin is calcium-dependent and requires the histidine-rich site formed at the dimer interface. *J Am Chem Soc.* (2013) 135:775–87. doi: 10.1021/ja3096416
123. Feinen B, Russell MW. Contrasting roles of IL-22 and IL-17 in murine genital tract infection by *Neisseria gonorrhoeae*. *Front Immunol.* (2012) 3:11. doi: 10.3389/fimmu.2012.00011
124. Quintana FJ. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. *Immunology.* (2013) 138:183–9. doi: 10.1111/imm.12046
125. Murray IA, Perdew GH. Ligand activation of the Ah receptor contributes to gastrointestinal homeostasis. *Curr Opin Toxicol.* (2017) 2:15–23. doi: 10.1016/j.cotox.2017.01.003
126. Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. *Front Cell Infect Microbiol.* (2018) 8:13. doi: 10.3389/fcimb.2018.00013
127. Million M, Tomas J, Wagner C, Lelouard H, Raoult D, Gorvel J-P. New insights in gut microbiota and mucosal immunity of the small intestine. *Hum Microbiome J.* (2018) 7–8:23–32. doi: 10.1016/j.humic.2018.01.004
128. Yitbarek A, Taha-Abdelaziz K, Hodgins DC, Read L, Nagy E, Weese JS, et al. Gut microbiota-mediated protection against influenza virus subtype H9N2 in chickens is associated with modulation of the innate responses. *Sci Rep.* (2018) 8:13189. doi: 10.1038/s41598-018-31613-0
129. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. *Cell Metab.* (2018) 28:737–49.e4. doi: 10.1016/j.cmet.2018.07.001
130. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity.* (2013) 39:372–85. doi: 10.1016/j.immuni.2013.08.003
131. Valeri M, Raffatelli M. Cytokines IL-17 and IL-22 in the host response to infection. *Pathog Dis.* (2016) 74:ftw111. doi: 10.1093/femspd/ftw111
132. Krishnan S, Ding Y, Saeedi N, Choi M, Sridharan GV, Sherr DH, et al. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. *Cell Rep.* (2018) 23:1099–111. doi: 10.1016/j.celrep.2018.03.109
133. Ismail AS, Severson KM, Vaishnava S, Behrendt CL, Yu X, Benjamin JL, et al. Gammadelta intraepithelial lymphocytes are essential mediators of host-microbial homeostasis at the intestinal mucosal surface. *Proc Natl Acad Sci USA.* (2011) 108:8743–8. doi: 10.1073/pnas.1019574108
134. Witter AR, Okunnu BM, Berg RE. The essential role of neutrophils during infection with the intracellular bacterial pathogen *Listeria monocytogenes*. *J Immunol.* (2016) 197:1557–65. doi: 10.4049/jimmunol.1600599
135. Nielsen MM, Witherden DA, Havran WL. Gammadelta T cells in homeostasis and host defence of epithelial barrier tissues. *Nat Rev Immunol.* (2017) 17:733–45. doi: 10.1038/nri.2017.101
136. Krishnan S, Prise IE, Wemyss K, Schenck LP, Bridgeman HM, McClure FA, et al. Amphiregulin-producing gammadelta T cells are vital for safeguarding oral barrier immune homeostasis. *Proc Natl Acad Sci USA.* (2018) 115:10738–43. doi: 10.1073/pnas.1802320115
137. Heiss CN, Olofsson LE. The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system. *J Neuroendocrinol.* (2019) e12684. doi: 10.1111/jne.12684

138. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell*. (2005) 122:107–18. doi: 10.1016/j.cell.2005.05.007
139. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. *J Immunol*. (2008) 180:5771–7. doi: 10.4049/jimmunol.180.9.5771
140. Cyktor JC, Turner J. Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. *Infect Immun*. (2011) 79:2964–73. doi: 10.1128/IAI.00047-11
141. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. *Crit Rev Immunol*. (2012) 32:23–63. doi: 10.1615/CritRevImmunol.v32.i1.30
142. Ueda Y, Kayama H, Jeon SG, Kusu T, Isaka Y, Rakugi H, et al. Commensal microbiota induce LPS hyporesponsiveness in colonic macrophages via the production of IL-10. *Int Immunol*. (2010) 22:953–62. doi: 10.1093/intimm/dxq449
143. Rivollier A, He J, Kole A, Valatas V, Kelsall BL. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. *J Exp Med*. (2012) 209:139–55. doi: 10.1084/jem.20101387
144. Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, et al. A single strain of *Clostridium butyricum* induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. *Cell Host Microbe*. (2013) 13:711–22. doi: 10.1016/j.chom.2013.05.013
145. Ochi T, Feng Y, Kitamoto S, Nagao-Kitamoto H, Kuffa P, Atarashi K, et al. Diet-dependent, microbiota-independent regulation of IL-10-producing lamina propria macrophages in the small intestine. *Sci Rep*. (2016) 6:27634. doi: 10.1038/srep27634
146. Quiros M, Nishio H, Neumann PA, Siuda D, Brazil JC, Azcutia V, et al. Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling. *J Clin Invest*. (2017) 127:3510–20. doi: 10.1172/JCI90229
147. Sassone-Corsi M, Raffatellu M. No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. *J Immunol*. (2015) 194:4081–7. doi: 10.4049/jimmunol.1403169
148. Crouzet L, Derrien M, Cherbuy C, Placade S, Foulon M, Chalin B, et al. *Lactobacillus paracasei* CNCM I-3689 reduces vancomycin-resistant *Enterococcus persistence* and promotes *Bacteroidetes resilience* in the gut following antibiotic challenge. *Sci Rep*. (2018) 8:5098. doi: 10.1038/s41598-018-23437-9

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Cheng, Ning, Chen and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.